Combining metabolic intervention with T-cell immunotherapy is safe and resulted in improved efficacy in two mouse models of solid tumors, providing an alternative combination strategy for boosting ...
Corbus Pharmaceuticals initiates combination cohort of CRB-701 study for solid tumors, focusing on HNSCC and cervical cancer. Data update expected this year. Corbus Pharmaceuticals Holdings, Inc.
SYDNEY and SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company ...
Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Overall, 14 ...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), and BeiGene, Ltd ...
FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR ...
SHANGHAI & SUZHOU, China--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results